Temporal Concept
Lexeo Therapeutics Reports Promising Early Data for Gene Therapy LX2006 in Friedreich Ataxia Cardiomyopathy
Lexeo Therapeutics, LX2006, Gene Therapy, Friedreich Ataxia, Cardiomyopathy, Clinical Trials, Rare Genetic Disorders
FDA Rejects Novo Nordisk’s Once-Weekly Insulin Icodec for Diabetes Treatment
FDA, Novo Nordisk, Icodec, Weekly Insulin, Diabetes Treatment, Type 1 Diabetes, Type 2 Diabetes, Complete Response Letter
Flagship’s Noubar Afeyan on Uncertainty, AI, and the Future of Biotechnology
, Noubar Afeyan, Flagship Pioneering, Biotechnology, Artificial Intelligence (AI), Uncertainty, Innovation, Future of Biotech, Moderna, Venture Capital,
Compensation Trends in the Pharmaceutical and Biotech Industry: 2023 Insights
pharmaceutical industry, biotech companies, median salary, employee pay, compensation trends, 2023
UniQure Wins First FDA RMAT in Huntington’s Disease After Strong Phase I/II Data
UniQure, Huntington’s disease, gene therapy, AMT-130, FDA, RMAT designation, Phase I/II clinical trials, neurodegenerative disorder, neurofilament light (NfL), disease progression, composite Unified Huntington’s Disease Rating Scale (cUHDRS).
Beacon Therapeutics Raises $170 Million to Advance Ocular Gene Therapy
Beacon Therapeutics, ocular gene therapy, J&J, Series B financing, AGTC-501, rare ophthalmology
Biopharma Layoff Tracker 2024: CureVac, Takeda, Aerovate and More Cut Staff
Biopharma, Layoffs, 2024, CureVac, Takeda, Aerovate, Job Cuts, Industry Trends
FDA Approves EPKINLY (Epcoritamab-Bysp) for Relapsed or Refractory Follicular Lymphoma
EPKINLY, epcoritamab-bysp, follicular lymphoma, FDA approval, relapsed or refractory, bispecific antibody, T-cell engaging, subcutaneous treatment
Silence’s siRNA therapy maintains Lp(a) lowering in cardiovascular study
Lp(a ), RNA, Small Interfering, Cardiovascular Diseases
iOnctura Secures €80 Million in Series B Financing to Advance Rare Eye Cancer Treatment
iOnctura, Series B financing, rare eye cancer, uveal melanoma, roginolisib, cancer treatment